Cytokinetics, Inc. (CYTK): New presentation at the 21st Annual Hear...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	42
Posts	2158
Boards Moderated	0
Alias Born	07/17/2014

H2R

Re: None

Monday, 09/11/2017 6:24:49 PM

Monday, September 11, 2017 6:24:49 PM

New presentation at the 21st Annual Heart Failure Society of America Scientific Meeting

Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, will be presented in a Rapid Fire Abstracts Presentation at the 21st Annual Heart Failure Society of America Scientific Meeting from September 16-19 in Dallas, TX.

Abstract Title: Effect of omecamtiv mecarbil in patients with ischemic and non-ischemic heart failure with reduced ejection fraction: Results from COSMIC-HF
Speaker: John Teerlink, M.D., Professor of Clinical Medicine at the University of California San Francisco and Director of Heart Failure at the San Francisco Veterans Affairs Medical Centers
Session Title: Rapid Fire Abstracts I
Location: Gaylord Texan Hotel & Convention Center, Grapevine 1-3
Date: Sunday, September 17
Time: 1:00 PM – 2:00 PM CDT

http://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-additional-results-cosmic-hf-be-0